U.S. Markets open in 40 mins

Zogenix, Inc. (ZGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.35+0.56 (+2.35%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close23.79
Open23.85
Bid22.05 x 800
Ask0.00 x 800
Day's Range23.50 - 24.53
52 Week Range16.65 - 57.22
Volume829,180
Avg. Volume1,032,653
Market Cap1.348B
Beta (5Y Monthly)1.76
PE Ratio (TTM)N/A
EPS (TTM)-9.20
Earnings DateAug 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.18
  • GlobeNewswire

    Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5

    EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, after the market close, and will host a corporate update conference call and webcast on Wednesday, August 5, 2020, at 4:30 PM Eastern Time. Conference Call Details Wednesday, August 5, at 4:30 PM Eastern Time / 1:30 PM Pacific Time Toll Free:866-269-4260  International:323-347-3612  Conference ID:8881331 Webcast:http://public.viavid.com/index.php?id=141049  About Zogenix Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, C-IV has been approved by the U.S. FDA and is under review in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy. In addition, the company has two late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a rare childhood-onset epilepsy and one for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. MT1621 is being developed through Modis Therapeutics, a Zogenix company.CONTACTS: Zogenix Melinda Baker Senior Director, Corporate Communications +1 (510) 788-8732  |  corpcomms@zogenix.com Investors Brian Ritchie Managing Director, LifeSci Advisors LLC +1 (212) 915-2578 | britchie@lifesciadvisors.com

  • Earnings Preview: Zogenix (ZGNX) Q2 Earnings Expected to Decline
    Zacks

    Earnings Preview: Zogenix (ZGNX) Q2 Earnings Expected to Decline

    Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Did Hedge Funds Make The Right Call On Zogenix, Inc. (ZGNX) ?
    Insider Monkey

    Did Hedge Funds Make The Right Call On Zogenix, Inc. (ZGNX) ?

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]